Live from AUA2022: Highlights in Advanced Prostate Cancer

Live from AUA2022: Highlights in Advanced Prostate Canceris a panel discussion filmed during the 2022 AUA Annual Meeting!

This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with advanced prostate cancer. Faculty will review the latest advances in prostate cancer including the many new FDA-approved agents, as well as existing standard therapies. Urologists will gain the ability to translate the latest scientific advances into their routine clinical practice, improving the care of men with advanced prostate cancer.


Acknowledgements

This educational activity is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Merck & Co., Inc.
  • Pfizer, Inc.

Target Audience

  • Urologists

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Describe recent developments in the medical management of advanced prostate cancer.
  2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
  3. 探讨晚期前列腺癌治疗的临床研究。
  4. Analyze the risks and benefits of treatment for advanced prostate cancer.
  5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.
Course summary
Available credit:
  • 1.00AMA PRA Category 1 Credit™
  • 1.00Non-Physician Participation
Course opens:
05/16/2022
Course expires:
05/16/2023
Rating:
0

Faculty disclosures will be posted here prior to the start of the course.

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Course Director(s)

Stephen Boorjian, MD

has afinancial relationship (Consultant or Advisor (Oncology)) with Prokarium; .
has afinancial relationship (Consultant or Advisor (Oncology)) with ArTara; .
has afinancial relationship (Consultant or Advisor (Oncology)) with FerGene; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Ferring; .
Faculty(s)

Leonard Gomella, MD

has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck Pharmaceuticals; .
has afinancial relationship (Health Publishing (Specialty Not Specified)) with Merck Manual; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Lantheus; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Astra Zeneca; .
has afinancial relationship (Health Publishing (Specialty Not Specified)) with Canadian Journal of Urology; .
has afinancial relationship (Intellectual Property Interest (Oncology)) with Thomas Jefferson University; .
has afinancial relationship (Health Publishing (Specialty Not Specified)) with Wolters Kluwer; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with MDx Health; .
has afinancial relationship (Health Publishing (Specialty Not Specified)) with McGraw Hill; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Exelixis; .

David Jarrard, MD

目前没有相关财务关系需要披露。

Alicia Morgans, MD, MPH

has afinancial relationship (Consultant or Advisor (Oncology)) with Advanced Accelerator Applications; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Merck; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Telix; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Advanced Accelerator Applications; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Novartis; .
has afinancial relationship (Consultant or Advisor (General Urology)) with BMS; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Janssen; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Progenics; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Astra Zeneca; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Pfizer; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Clovis; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Myriad; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Genetech; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Myovant; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Dendreon; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Lantheus; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Sanofi; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Genetech; .

METHOD OF PARTICIPATION:

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and/or listening to the podcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hours

Release Date: May, 2022
Expiration Date: May, 2023

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring activity for a maximum of 1.0AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified forAMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

本协会的政策是确保CME活动所包含的内容是有效的、公平的、平衡的、科学严谨的,并且不带有商业偏见。

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:

所有披露的信息将由项目/课程主管或编辑审查,以确定利益冲突。同行评审人员将与项目主管和/或编辑合作,记录管理和解决利益冲突的机制,并在实施前记录活动的最终批准。Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00AMA PRA Category 1 Credit™
  • 1.00Non-Physician Participation
Pleaseloginorregisterto take this course.

Registration for this course is complimentary.


AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance, please contact Education@AUAnet.org.